Form 4: Immunome Director Carol Schafer Acquires Stock Options
SEC Form 4
Director Carol Schafer acquired stock options in Immunome Inc. on June 13, 2024.
Summary
- Carol Schafer, a director of Immunome Inc., filed a Form 4 on June 18, 2024, reporting a transaction.
- On June 13, 2024, Schafer acquired 11,333 stock options with an exercise price of $16.04.
- These options vest in four quarterly installments starting June 13, 2024, and expire on June 12, 2034.
- Following the transaction, Schafer directly owns 11,333 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction (stock option grant) for a director, suggesting standard compensation practices.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of earliest transaction: Carol Schafer acquired stock options. |
| 06/13/2024 | Options vest in 4 quarterly installments, commencing from this date. |
| 06/12/2034 | Expiration date of the stock options. |
| 06/18/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.